<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

Back to Press Releases

NeoTract Inc. Receives #Gamechanger Award for Innovation


PLEASANTON, Calif.– April 13, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company has been recognized with the Innovation Tri-Valley Leadership Group’s #Gamechanger Award.

The #Gamechanger Awards recognize innovations that create better products, processes and services with proven regional and global impacts. Last week, #Gamechanger Award recipients were presented with awards in partnership with the mayors and economic development directors of the cities leading the Innovation Tri-Valley Group, a collaborative group of industry leaders, champions companies that model a culture of innovation and collaboration in the regional economy. 

NeoTract manufactures the UroLift® System, a revolutionary, minimally invasive approach to treating benign prostatic hyperplasia (BPH), also called enlarged prostate.

“We are proud of the UroLift System, a game-changer that is setting a new standard for the treatment of BPH, a common men’s condition that severely impacts quality of life,” said Dave Amerson, President and CEO, NeoTract, Inc. “It is gratifying to be recognized as an innovative company, and we are thrilled to be a part of this incredibly supportive and collaborative community.”

Last week, the company announced positive five-year results of the pivotal study of the UroLift System, which demonstrate the durable benefits of the treatment. The UroLift System procedure can be performed efficiently and effectively under local anesthesia, typically without the need for a postoperative urinary catheter. Symptom relief is achieved rapidly, within two weeks, and data from the study demonstrates that results at one month are very similar to what can be expected at five years. Serious side effects of traditional surgery are avoided, and the UroLift System treatment is the only procedure shown to not cause sustained sexual issues.

“The Tri-Valley is where the best minds in the world are at work,” said Dale Eldridge Kaye, CEO of the Innovation Tri-Valley Leadership Group. “NeoTract is a company that truly values innovation and collaboration, and we are proud to have the company in our community.”

About Innovation Tri-Valley (ITV)

Innovation Tri-Valley (ITV) is a collaborative group of industry leaders who are building a robust ecology of innovation in California’s Tri-Valley.  By bringing together companies, non-profits, and regional thought leaders deeply involved in innovation, ITV is improving the business climate of the region, spurring job growth, and expanding the vibrant Tri-Valley community.    For more information, please visit www.innovationtrivalley.org

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

#  #  #

Media Contacts:
Nicole Osmer


MAC00426-01 Rev A